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ABSTRACT 
The liver is an important organ in the body. It is located under the rib cage on the 
right side. The liver performs many important functions, it processes food for nutrients 
that the body requires and also helps in the detoxification of harmful materials. Like any 
organ in the body, the liver is susceptible to diseases such as liver cancer. Liver cancer is 
the growth and spread of unhealthy cells of the liver. There are several risk factor for 
liver cancer, these are: Cirrhosis (scarring of the liver), long term hepatitis B and hepatitis 
C infection and diabetes patients with long term drinking problem. Hepatocellular 
Carcinoma is the most common form of liver cancer in adult population which begins in 
the main type of liver cell (hepatocyte). Because Hepatocellular carcinoma starts from the 
primary liver cell itself (hepatocytes), as such it is a primary liver cancer. About 30,000 
Americans are diagnosed with primary liver cancer yearly, making it an important 
disease that plaques our society and therefore needs proper diagnosis. 
In clinical evaluation of primary liver cancer such as HCC, the use of medical 
imaging technology has been commonplace. Most medical facilities across the country 
and globally typically use Computed Tomography (CT) and/or Magnetic Resonance 
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Imaging (MRI) in the diagnosis and treatment follow up of Hepatocellular carcinoma. 
The medical imaging devices are used to determine the extent and volume of the tumor of 
the cancerous liver cells. In clinical trials involving the imaging of HCC tumors, the 
typical protocol used in the CT imaging of HCC involves the use of contrast enhanced 
dual phase acquisition. This approach is based on the physiology of the blood flow 
through the liver. Since HCC tumors are hypervascular in nature, it would thus be more 
apparent in the arterial phase of an acquired CT image. The aforementioned characteristic 
was tested with a volume paradigm which measure and compare the volume of both the 
arterial phase and portal venous phase acquired images in the experiment. Overall this 
study helps in furthering goals to reduce the patient dose from the x-ray tubes during 
clinical trials. The results of the experiments (n = 19, t = 0.67, p = 0.26), indicates no 
significant difference between the volume of the HCC tumor images acquired both in the 
AP and PVP. 
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INTRODUCTION 
 The liver is not only one of the largest organs in the human body; it is also one of 
the most important organs in the body.  The liver helps the body filter harmful substances 
from the blood and makes substances that help to digest food to produce energy reserves 
for the body. Proper functioning of the liver thus is inherent to overall functioning of the 
body. However, the liver is prone to diseases just like most organs in the body. Primary 
liver cancer is a form of cancer that starts in the liver and may spread to other parts of the 
body. Such type of liver cancer is hepatocellular carcinoma which is the most common 
type of primary liver cancer. Hepatocellular Carcinoma’s (HCC) has no unique cause, but 
it is secondary to other liver diseases such as viral hepatitis and cirrhosis. Treatment for 
HCC’s varies depending on the prognosis of individuals who have this disease based on 
their doctor’s evaluation.   Overall, treatment options for HCC depend on the size of the 
tumor. The advent of medical imaging technology has been tremendously important to 
staging of this disease by measuring the size of the tumor.  
Different types of imaging modalities are used for the evaluation of HCC tumors 
in the liver; importantly is the Computed Tomography that has the advantage of being 
very fast and gives good soft tissue contrast when combined with intravenous 
administration of an exogenous contrast material injection. Dual phase contrast enhanced 
CT imaging has been a very important procedure used by physicians to scout patients 
liver for potential tumors during clinical trials. Dual phase imaging is particularly useful 
for liver imaging based on the physiology of this organ. The two phases in which the 
images are acquired are the hepatic arterial phase and the hepatic venous phase. The 
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phases are named based on the vessels that supply the blood to the liver at specific times 
at which it takes an intravenously injected iodine contrast bolus to get to the liver. The 
hepatic artery delivers 20-25% of blood flow to the liver while the portal vein delivers the 
remaining 75-80%. During a dual phase imaging of the liver, post injection of an 
intravenous iodine contrast bolus, the effect of the contrast material delivered to the liver 
via the hepatic artery will be seen approximately 20-30 seconds while that of the portal 
vein will be seen at about 45-55 seconds. The blood flowing through the portal vein takes 
a little longer to get to the liver because it has to circulate through the spleen and 
mesentery before reaching the liver.  
Not only is CT an imaging modality used in clinical evaluation of abdominal 
diseases due to its ability to show contrast between soft tissues, importantly, it can help 
differentiate different types of tumors associated with the liver. Hypervascular tumors 
such as hepatocellular carcinoma are more distinct and well delineated in the arterial 
phase of CT image acquisition post contrast injection. However, hypovascular tumors are 
not distinct and well delineated in the arterial phase of acquisition.  
In the venous phase of the contrast enhanced CT images, the reverse is the case, as 
hypovascular focal tumors are more distinct in comparison to the rest of the liver 
parenchyma. 
When an intravenous contrast bolus is injected to the blood stream, the contrast 
material is delivered to the hepatic artery, and will be seen approximately 20-35 seconds 
before the effect of the contrast material delivered by the portal vein will be seen at 35- 
45 seconds. The concentrated level of the injected contrast in the arterial blood flow 
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opacifies the images of tumors in such phase, in comparison to the parenchyma 
background making them more visible and well delineated. Since we know that HCC 
tumors are inherently well differentiated and delineated in the arterial phase of a contrast 
enhanced dual phase CT image, this thesis work compares and evaluate the volume of 
HCC tumors acquired through both the AP and PVP for clinical trial purpose. The 
specific parameter being studied in this experiment is the difference in volume of tumor 
obtained for individual subjects in both the AP and portal PVP of the acquired contrast 
enhanced CT images. The experimental work seeks to determine if there is a significant 
difference between the AP and the PVP volumes of an HCC tumor.   
For clinical diagnosis and during clinical trials, it is worth  noting that  abdominal 
contrast enhanced CT imaging of the liver is also helpful in deciphering other types of 
potential tumors found both in the different part of the abdominal cavity and importantly 
in the  liver.  
Figure 1: Example of a HCC tumor in AP CT Image.     Figure 2: Example of a HCC tumor in PVP CT Image. 
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Previous literatures have described the physiology of hypervascular and 
hypovascular tumors in terms of blood flow and how an injected contrast material will 
get to the liver within a certain period. Furthermore, these literatures described the 
difference between hypervascular and hypovascular tumors in terms of how they 
attenuate in comparison to the background liver parenchyma post contrast injection. Also, 
some literatures have described the different segmentation algorithms and their 
shortcomings that could automatically segment hypervascular and hypovascular tumors 
in a dual phase contrast enhanced CT images. However, there were limited resources that 
compared the segmented tumors in both the arterial and the portal venous phase in terms 
volume. This became a springboard for this study, with a primary objective to 
corroborate tumor size of hypervascular tumors (HCC precisely) of subjects by 
segmenting its dual phase acquired CT images manually and comparing the volume 
values of both phases.  
If the hypothesis of this study is corroborated with positive experimental results, 
this research will serve as a background for limiting the x-ray dose patients receives from 
CT when their HCC tumor is being evaluated for clinical trials. 
 
Subsection One (Background) 
 
Computed tomography is a non- invasive imaging device that is used for imaging 
bones, soft tissues and blood vessels. Computed tomography today is used in the 
diagnosis of many ailments, as it allows doctors to view slices and cross sections of bones 
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such as the skull, hemorrhages in blood vessels and importantly tumors in both bones and 
soft tissues. CT imaging of the liver has been very important in clinical trials during the 
development of novel therapeutic agents, including those directed at HCC. Most clinical 
trials involving imaging of liver cancers are based on understanding how cancer tumors 
respond to therapies by staging the disease through visible changes observed via imaging 
modalities. CT works similar to an x-ray. The conventional x-ray imaging operates based 
on the absorption of incident x-rays on a body. These x-rays are focused on a part or 
section of the body. As the x-rays pass through the body, some x-ray photons will be 
absorbed by the body, while others will not be absorbed. The non-absorbed or transmitted 
x-rays that emerge from the body will interact with a detection device and thus form a 
two-dimensional image of the body part. 
CT scanning is very different form the regular projectional x-ray imaging. It 
differs by the fact that a two dimensional image is acquired and in the manner that the 
image output is provided by its detector. A typical  CT scanner creates a two dimensional 
cross sectional images (slice) of three dimensional body structure by utilizing a computer 
based mathematical technique called reconstruction. The CT scan has many important 
part that makes acquiring the cross sectional images of a body possible. These parts 
include the gantry, x-ray tube, collimators, filters, detectors and the data acquisition 
system. 
The first major component of the CT imaging system is the gantry and the patient 
table or couch. The gantry is a moveable frame that contains the x-ray tube, collimators, 
filters, detectors and the data acquisition system. It also contains the rotational component 
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which includes the slip ring systems and all associated electronics such as the gantry 
angulation motors and positioning laser lights. The slip ring that is found on the gantry of 
the CT system helps for continuous scanning without interference by cables. Gantry 
angulation which is manufacturer specific, allows the operator to align pertinent anatomy 
with the scanning plane. The opening that allows patient access to the CT scanner 
through the gantry is known has the aperture. This aperture varies depending on the 
manufacturer. Generally, gantry aperture ranges from 50-85 cm while CT’s with larger 
apertures are typical used for special procedures such has large volume biopsy 
procedures. These larger aperture CT’s allow for easy manipulation of biopsy 
equipment’s and as such reduces the risk of injury to the patient during scanning. The 
entire diameter of the gantry aperture is not the scanning diameter of the CT system; it is 
lesser than the gantry diameter. Lasers or high intensity lights serve as the anatomical 
positioning guides that reference the center of the axial, coronal, and sagittal imaging 
planes of the CT scanner. 
The procedures for acquiring CT images, allows for significant radiation exposure 
factors over a short period of time (high mA and kVp). Advancements in CT designs 
such as in the case of modern helical/spiral CT allows for continuous scanning while the 
patient table moves through the gantry. Such continuous scanning leads to the buildup of 
heat on the x-ray tube and may causes heat stress or possible destruction of the material 
that makes up the x-ray tube if it does not have a mechanism to dissipate the heat. CT x-
ray tubes are designed with materials with high heat capacity so as allow optimal 
operation of the tube and avoid operation damage to the tube. In CT, the x-ray tubes are 
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designed to absorb high heat levels generated from the high speed rotation of the anode 
and the bombardment of electrons upon the anode surface. Modern CT systems are 
designed with x-ray tubes with heat capacity of 3.5 to 5 million heat units (MHU).  
For the CT scanners to be able to operate continuously without interruptions due 
to overheating, the x-ray tubes must possess the capacity to dissipate heat at a high rate. 
Most CT tubes utilize oil and air cooling system to eliminate heat and allow for 
continuous proper functioning of the x-ray tube. In addition, the CT anode has a large 
diameter with graphite backing that allows is it to absorb and dissipate a large amount of 
heat.   
When x-ray beams travel through the patient, these are attenuated by the 
anatomical structures it passes through. Unlike conventional x-rays that utilize a film 
screen system as its primary image receptor to collect the attenuation information, CT 
beam is collected on a detector. The CT process relies on the collection of attenuated 
photon energy and converting them to an electrical signal, which will be further 
converted to digital signal for computer reconstruction. 
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Subsection Two (Theory) 
The detection of liver masses in CT imaging is based on the x-ray attenuation 
difference between the tumor and the normal liver mass. Liver tumors may not be visible 
in non-contrast enhanced CT because the inherent contrast between the tumor and the 
surrounding liver parenchyma is too low. An intravenous (IV) contrast is needed to 
increase the conspicuity of tumor. There is a dual supply of blood to the liver; the blood 
supply to the normal liver parenchyma is supplied by the hepatic artery (approx. -75%) 
and the portal vein (approx. -25%). In case of a normal liver with an infusion of the IV 
contrast, the liver would enhance maximally in the portal venous phase. All liver tumors 
receive the majority of their blood supply from the hepatic arterial system, so when they 
enhance, it will be in the arterial phase. The difference in blood supply to the liver, leads 
to different enhancement patterns between the liver tumors and normal liver parenchyma 
in different phases of the enhancement. 
In the arterial phase of enhanced CT imaging of the liver, hypervascular tumors 
are enhanced via the hepatic artery before the rest of the surrounding parenchyma 
enhances. This is because contrast is not yet in the portal venous system. The 
enhancement of the hypervascular tumor in the arterial phase of its enhancement makes it 
visible as an area of hyperattenuation compared to the relative hypoattenuation of the rest 
of the liver. But when the surrounding liver parenchyma starts to enhance in the portal 
venous phase, the hypervascular tumors may start to be obscured. 
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During the portal venous phase, hypovascular tumors are detected when the 
normal parenchyma of the liver enhances completely. The hypovascular tumors will be 
visible as hypodense tumors in a relatively hyperdense liver. 
For the optimal enhancement of hypervascular tumors, optimal timing of the scan 
and the speed of the contrast injection are very important. The infusion of an IV contrast 
into the liver during arterial phase CT imaging will see the blood containing the contrast 
material enhancing the tumor from about 20 seconds to 30 seconds. The early phase of 
the enhancement starts at about 18 seconds and as such the tumor is not hyperdense 
compared to its liver parenchyma. At 35 seconds – late arterial/early portal venous 
enhancement, maximum enhancement of the hypervascular tumors is achieved, as it 
becomes hyperdense compared to the rest of the liver parenchyma. At the late arterial 
enhancement (35 seconds), the portal venous system starts to enhance, until the entire 
liver is concentrated with the contrast at the late portal venous enhancement - 75 seconds. 
At this point characterized hypovascular tumors become visible. 
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METHODS (research-based) 
 
 This retrospective research study includes abdominal CT images of patients who 
were diagnosed with focal HCC at the Boston Medical Center (BMC). The CT images 
for this study are from patients who have undergone a dual phase contrast enhanced CT 
images within the past 10 years. The images were acquired under the BMC standard liver 
imaging protocol of 1.25 mm slice selection thickness. The data sets obtained from the 
CT images of the patients for this research included both males and female patients. 
While there was no age restriction on the subjects used, the sample population for this 
research was entirely adult based as a result of pathological conditions that limits 
hepatocellular carcinoma mostly to adult populations. There was variation in the race and 
ethnicity of the subjects associated with the data set used for this research.  
The inclusion criteria for this research are individual subject images of 
pathologically diagnosed HCC focal tumors that are visible and well circumscribed in 
both the arterial and portal venous phase of a contrast enhanced dual phase CT images, 
while the exclusion criteria are patients whose image contains multiple tumors. For this 
project, the intended number of subjects was 20, as that was within the range of subject 
used in similar experiments. Over 30 dual phase abdominal CT images of patients with 
focal HCC was examined for this experiment, with 19 meeting the inclusion criteria.  
The experimental design for this research was simple and straightforward. The images 
used in acquiring data for this research was first de-identified with a specialized DICOM 
de-identifier program before they were screened for both inclusion and exclusion factors. 
After the aforementioned steps were taken, the identified tumors in both phases of 
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acquisition were then segmented manually using “ImageJ” software. The ImageJ 
software is an open source image processing software that is created and made available 
by the National Institute of Health (NIH). This software is used in the segmentation of 
individual tumors and overall in the determination of the volume of these tumors. Each 
subject that was included in this research was assigned a number; the subjects range from 
P1 through P19. The segmentation was done twice for each phase of the image 
acquisition and the average volume value was then tabulated. There was no control group 
in this experiment; however the control factor used was that the slice selection for 
segmentation in each phase was the same for the repeated segmentation. 
 
 
Subsection One (Image Processing) 
In processing the images that were available for this research, the images were 
first identified to meet the initial criteria of being an HCC tumor that is wells 
circumscribed by Dr. Stephan Anderson and made available through the Boston Medical 
Center (BMC) picture archiving communication system (PACS). The images were 
downloaded on a secure system and instantly de-identified using DICOM anonymizer 
PRO software. All the downloaded images were then reviewed for inclusion criteria. The 
images that met the inclusion criteria were downloaded, divided into the arterial and 
venous phases of the acquisition and further saved in folders named by their respective 
acquisition phases. Both folders were subsequently saved into a supra-folder that was 
named with their individual subject identification numbers. The images were processed 
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by uploading individual images on the ImageJ platform. Uploading the images on the 
ImageJ platform was accomplished by clicking on file menu on the ImageJ platform, 
under the file menu, the import command was clicked. The location of the folder 
containing the images was located and the specific folder needed to be processed 
uploaded.  
    
Figure 3: Process of importing images on to the ImageJ Software Platform 
 
Once the specific image was uploaded on the ImageJ platform, the software 
downloads all the image slices on one moveable panel. The images were inspected 
through for a visible HCC tumor that is well circumscribed. When the tumor was 
identified, it was segmented in multiple slice panels if visible on multiple subsequent 
panel.  
The segmentation was performed on the ImageJ platform by using the freehand 
selection tool to manually draw a region of interest (ROI) along the circumference of the 
tumor at each slice selection. 
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Figure 4: The freehand selection tool for drawing ROI on images loaded on ImageJ. 
 
 
 
 
 
               
                              Figure 5: Example ROI drawn on an HCC tumors with the freehand selection tool. 
 
 
Once the selection was done at each slice frame, the data containing the area, of 
the segmented tumor is computed with the command “ctrl + M” on the ImageJ software 
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using the keyboard. This displays the tabulated results of the processed image as seen 
below on figure 5. The areas in the displayed tables were averaged to get the mean values 
of the individual images for both the arterial and portal venous phases. The mean value 
obtained from the segmented slices was multiplied by the slice thickness (1.25 mm) and 
the number of slides which an ROI was acquired in order to determine the mean volume 
in (mm3). The mean volumes were converted to cm3 by dividing the numbers by 1000. 
This was done in order to lessen the digits and make it easy to statistically analyze the 
data. 
 
   
  
  
  
  
    
                      
Figure 6: The tabulated output of a processed selected ROI of an image loaded on the ImageJ 
platform. 
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RESULTS 
 The profound text of my thesis goes here. The profound text of my thesis goes 
here. The profound text of my thesis goes here. The profound text of my thesis goes here. 
The profound text of my thesis goes here. 
 In the statistical analysis of the data of the area abstracted form the ROI drawn on 
each tumor on both phases of the HCC images, Microsoft Excel was used in the analysis 
of these data. In both phases of the image acquisition, the image processing was done 
twice and the values computed and tabulated in the tables 1 - 5 below. 
Table 1: Data for the computed volume of two individually measured ROI of HCC tumors in both 
arterial and portal venous phase CT image. 
Patient 
Arterial 1 
(cm3) 
Arterial 2 
(cm3) 
Venous 1 
(cm3) 
Venous 2 
(cm3) 
1 2.04439625 2.20632 3.99467125 4.00185 
2 58.69219 58.2718375 28.7996375 28.3785425 
3 4.1373325 3.83060125 4.65458125 4.27165 
4 0.663385 0.691545 2.337825 2.29071125 
5 4.46553 4.5315975 3.86496375 3.57199125 
6 0.13339625 0.1287275 0.05602625 0.05869375 
7 13.300805 13.26866875 1.363677917 1.383865417 
8 12.0543375 11.90169625 12.42450875 10.95618375 
9 0.79935375 0.78513625 0.512425 0.50413375 
10 0.69815875 0.68323375 0.57627125 0.60777875 
11 1.36944625 1.35955875 1.375625 1.3181525 
12 0.69832 0.6834875 0.3559575 0.3683175 
13 0.10604 0.1208625 0.09691875 0.078675 
14 0.10604 0.1208625 0.07910125 0.0803375 
15 0.10544 0.10886875 0.0565775 0.05143375 
16 0.17424625 0.2332575 0.1649525 0.213741 
17 2.11832875 2.12909625 1.6074525 1.85131875 
18 0.59927125 0.60238375 0.66231125 0.6662025 
19 0.79099625 0.779825 0.67024625 0.6596075 
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Descriptive statistics was first used to analyze these data, by tabulating the 
average values of the two area values in both the arterial and the portal venous phases. 
The tables below show the tabulated average values of the areas in both phases. 
Table 2: The average volume of the segmented tumors from both the AP and PVP. 
Patient  Arterial Avg. (cm3) Venous Avg. (cm3) 
1 2.125358125 3.998260625 
2 58.48201375 28.58909 
3 3.983966875 4.463115625 
4 0.677465 2.314268125 
5 4.49856375 3.7184775 
6 0.131061875 0.05736 
7 13.28473688 20.60657563 
8 11.97801688 11.69034625 
9 0.792245 0.508279375 
10 0.69069625 0.592025 
11 1.3645025 1.34688875 
12 0.69090375 0.3621375 
13 0.11345125 0.087796875 
14 0.11345125 0.079719375 
15 0.107154375 0.054005625 
16 0.203751875 0.18934675 
17 2.1237125 1.729385625 
18 0.6008275 0.664256875 
19 0.785410625 0.664926875 
 
 
The mean values for both the arterial and the portal venous phases of the acquired 
image of the HCC tumors were used to determine the relevance through precision of 
individual data points collected. Furthermore, relevance of the data points collected for 
both phases of the acquired images was also determined by setting 0.1 as the maximum 
threshold deviation of these points from the mean value of both the arterial and the portal 
venous phases. The 0.1 which is a small number is just an arbitrary limit set for the data, 
in order to keep the data set concise and consistent. The tables 3- 4, shows the deviations 
from the mean value. 
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Table 3: Mean deviations for the dual volume measurements of the AP tumors. 
Patient 
 Arterial 
Avg. (cm3) 
Arterial 1 – 
Arterial 
Avg.  (cm3) 
Arterial 2 – 
Arterial 
Avg. (cm3) 
1 
2.125358125 -0.080961875 0.080961875 
2 
58.48201375 0.21017625 -0.21017625 
3 
3.983966875 0.153365625 -0.153365625 
4 
0.677465 -0.01408 0.01408 
5 
4.49856375 -0.03303375 0.03303375 
6 
0.131061875 0.002334375 -0.002334375 
7 
13.28473688 0.016068125 -0.016068125 
8 
11.97801688 0.076320625 -0.076320625 
9 
0.792245 0.00710875 -0.00710875 
10 
0.69069625 0.0074625 -0.0074625 
11 
1.3645025 0.00494375 -0.00494375 
12 
0.69090375 0.00741625 -0.00741625 
13 
0.11345125 -0.00741125 0.00741125 
14 
0.11345125 -0.00741125 0.00741125 
15 
0.107154375 -0.001714375 0.001714375 
16 
0.203751875 -0.029505625 0.029505625 
17 
2.1237125 -0.00538375 0.00538375 
18 
0.6008275 -0.00155625 0.00155625 
19 
0.785410625 0.005585625 -0.005585625 
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Table 4: Mean deviations for the dual volume measurements of the PVP tumors 
Patient 
Avg. Venous 
(cm3) 
Venous 1 - 
Venous avg.  
(cm3) 
Venous 2 - 
Venous avg.  
(cm3) 
1 
3.998260625 -0.003589375 0.003589375 
2 
28.58909 0.2105475 -0.2105475 
3 
4.463115625 0.191465625 -0.191465625 
4 
2.314268125 0.023556875 -0.023556875 
5 
3.7184775 0.14648625 -0.14648625 
6 
0.05736 -0.00133375 0.00133375 
7 
20.60657563 -0.151405625 0.151405625 
8 
11.69034625 0.7341625 -0.7341625 
9 
0.508279375 0.004145625 -0.004145625 
10 
0.592025 -0.01575375 0.01575375 
11 
1.34688875 0.02873625 -0.02873625 
12 
0.3621375 -0.00618 0.00618 
13 
0.087796875 0.009121875 -0.009121875 
14 
0.079719375 -0.000618125 0.000618125 
15 
0.054005625 0.002571875 -0.002571875 
16 
0.18934675 -0.02439425 0.02439425 
17 
1.729385625 -0.121933125 0.121933125 
18 
0.664256875 -0.001945625 0.001945625 
 19 
0.664926875 0.005319375 -0.005319375 
   
 
Finally, a simple right tail paired sample t-test was performed on the both arterial 
and venous average HCC volume values to determine if or not there is a significant 
difference between them. 
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Table 5: Output of the computed simple right tail t-test of the AP and PVP liver tumor volumes. 
Patient Avg. Arterial (cm3) Avg. Venous (cm3) 
1 2.125358125 3.998260625 
2 58.48201375 28.58909 
3 3.983966875 4.463115625 
4 0.677465 2.314268125 
5 4.49856375 3.7184775 
6 0.131061875 0.05736 
7 13.28473688 20.60657563 
8 11.97801688 11.69034625 
9 0.792245 0.508279375 
10 0.69069625 0.592025 
11 1.3645025 1.34688875 
12 0.69090375 0.3621375 
13 0.11345125 0.087796875 
14 0.11345125 0.079719375 
15 0.107154375 0.054005625 
16 0.203751875 0.18934675 
17 2.1237125 1.729385625 
18 0.6008275 0.664256875 
19 0.785410625 0.664926875 
 
t-Test: Paired Two Sample for 
Means 
  
Arterial 
average 
Venous 
Average 
Mean 5.407752105 4.300855914 
Variance 179.6991232 60.48633936 
Observations 19 19 
Pearson Correlation 0.903738551 
Hypothesized Mean Difference 0 
df 18 
t Stat 0.670733493 
P(T<=t) one-tail 0.255452893 
t Critical one-tail 1.734063607 
P(T<=t) two-tail 0.510905787 
t Critical two-tail 2.10092204   
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DISCUSSION 
 
 Dual phase computed tomography imaging of the liver is often being used in the 
treatment evaluation and staging of liver tumors such as HCC during clinical trials. 
Hepatocellular carcinoma also known as primary liver carcinoma is a form of liver cancer 
that accounts for most liver cancers that is seen in the human population till date. A dual 
phase imaging protocol has become the standard method for imaging HCC tumors in the 
liver using CT due to the basic physiology of the liver in terms of its blood supply and 
distribution function. In this study, volume paradigm was used in the accessing the 
difference in the volume of both phases and potentially negating the usefulness of the 
portal venous phase in the imaging protocol. In assessing the differences in the volumes 
of both phases, an experimental design using volume paradigm was designed and used in 
assessing the difference in the volume of both phases and potentially negating the 
usefulness of one of the image acquisition phase during clinical trials. The objective of 
the experiment is determine if there is a statistical difference between the volumes of the 
arterial and venous acquired images of the same patient with focal HCC tumors in a 
randomly sampled population.  
Descriptive statistics was first used in testing of the hypothesis for this study. The 
HCC tumors in both the arterial and portal venous phase of the acquired images for the 
19 subjects in this study were manually segmented two times each within 24 hours. The 
segmentation was done twice on both phases of the image acquisition and the mean of the 
segmented areas subtracted from both volumes values of the segmented images in both 
phases of the acquired image in order to avert systematic errors and also limit the huge 
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fluctuations in the data set. The threshold value set for the deviation of the both data 
points in phase of the acquired image was at 0.1cm3, as it is believed to be a relatively 
small value based on the descriptive statistical parameters used in analyzing these dataset. 
The result of this statistical analysis as seen on table 5 indicates that the data collected 
from the segmentation of the HCC tumor in each phase of the image acquisition were 
similar and useful towards further analysis via inferential statistics. 
The inferential statistics computed for the data between the volume of the tumor 
in both phases of the acquired images gave values for (t = 0.67, P = 0.26). Since the P 
value for the one tailed sample t test is greater than 0.05, the null hypothesis which 
presumes the equality of both the volumes of tumors acquired in the arterial and the 
portal venous phase to be true. 
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CONCLUSION 
The results of the paired t-test for this study went contrary to the underlying 
hypothesis for this experiment which presumes significant difference in the volume of the 
tumor of both the AP images compared to the PVP images. The patient populations that 
constitute the subject in which the data for this experiment was derived are adult 
population of different body mass index, with pathologically identified HCC tumors. 
Since the results of the experiment showed no significant difference in the volumes of 
HCC in AP and PVP images of a CT scan, it can be deduced that either phase can be used 
to measure tumor volume in the liver for clinical trial purpose. This is important as it 
limits the overall patient exposure to x-ray beams from the CT x-ray tube. This idea 
supports the core of the experiments hypothesis that assumes the removal of negligible 
phase of the imaging acquisition phase (either AP or PVP), as determined by a qualified 
physician during clinical trials only.  
In conducting this research and evaluating the results of its statistically analyzed 
data, it can be deduced that the dual phase imaging of pathologically determined HCC 
will still be common place for clinical diagnosis. This is due to the sensitivity that the 
dual phase imaging provides in determining other non-vascular tumors that may have 
being missed during earlier diagnosis of patients.  
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